MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported ...
- Preliminary Unaudited Fourth Quarter 2020 Revenue Expected to be $27.7 to $28.1 Million - MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat ...
It has been about a month since the last earnings report for Intersect ENT . Shares have lost about 1.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with ...
A month has gone by since the last earnings report for Intersect ENT . Shares have added about 17.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
Preliminary and unaudited revenue in the range of $27.7 to $28.1 million. SINUVA recorded strong quarterly revenue of approximately $2.5 million. VENSURE, for sinus balloon dilation, an acquired ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results